Abstract

Plasma membranes represent pharmacokinetic barriers for the passive transport of site-specific drugs within cells. When engineered nanoparticles (NPs) are considered as transmembrane drug carriers, the plasma membrane composition can affect passive NP internalization in many ways. Among these, cholesterol-regulated membrane fluidity is probably one of the most biologically relevant. Herein, we consider small (2–5 nm in core diameter) amphiphilic gold NPs capable of spontaneously and nondisruptively entering the lipid bilayer of plasma membranes. We study their incorporation into model 1,2-dioleoyl-sn-glycero-3-phosphocholine membranes with increasing cholesterol content. We combine dissipative quartz crystal microbalance experiments, atomic force microscopy, and molecular dynamics simulations to show that membrane cholesterol, at biologically relevant concentrations, hinders the molecular mechanism for passive NP penetration within fluid bilayers, resulting in a dramatic reduction in the amount of NP incorporated.

Highlights

  • Plasma membranes represent pharmacokinetic barriers for the passive transport of site-specific drugs within cells

  • Balanced hydrophobic and electrostatic effects at the bilayer interface have been revealed as a distinguishing feature for promoting and guiding the passive incorporation of amphiphilic drugs[4,12−16] or amphiphilic-based drug carriers into cells

  • The impact of membrane fluidity in shaping passive NP uptake has primarily been addressed using biomimetic membrane models composed of phosphocholines (PCs), the main plasma membrane components

Read more

Summary

Introduction

Plasma membranes represent pharmacokinetic barriers for the passive transport of site-specific drugs within cells.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call